FDA and NMPA Approve New State-of-the-Art Contact Lens Manufacturing Facility for Euclid Systems Corporation
The US FDA and Chinese Regulatory Authority (NMPA) have approved Euclid Systems Corporation, is a Global Leader in Myopia Management and Advanced Orthokeratology, to manufacture the Euclid Emerald™ line of contact lenses in a new, state-of-the-art facility located in Sterling, Virginia. The new space is more than triple the size of the company’s current facility, allowing Euclid to keep up with the growing worldwide demand for its advanced orthokeratology lens design.
“With this new, state-of-the-art facility, Euclid has the space it needs to grow as we serve the rapidly expanding Orthokeratology market, providing improved vision and quality of life to kids around the world,”
said Michael Ross, chairman and chief executive officer, Euclid Systems Corporation.
Euclid also plans to transition to a custom automated platform for manufacturing, which will help the company better serve its customer base around the world.
The announcement of the new facility comes on the heels of Euclid receiving the prestigious award of “Public Trusted Brand” by the 11th Healthy China Forum earlier this year. The award is a testament to the company’s devotion to helping more children around the world realize their full potential through Proactive Myopia Management.
“The approval of our Sterling manufacturing facility comes at a critical time of increasing awareness of myopia as a global epidemic, global demand, and increased interest on the quality and safety of Euclid’s products,”
said Sandra Gilbert, vice president, global quality and regulatory compliance, Euclid Systems Corporation.
With evolved resources and targeted programs, Euclid is helping to Shape the Future of Vision through Orthokeratology and Myopia Management. For more information about the company and its offerings, please email PR@euclidsys.com or call (800) 477-9396.
About Euclid Systems Corporation
Euclid Systems Corporation is a world leader of Myopia Management and manufacturer of Advanced Orthokeratology lens products. Multiple clinical studies worldwide by prestigious independent researchers have proven the effectiveness of Orthokeratology, and specifically the Euclid Emerald™ lens, on slowing the progression of myopia. The Euclid Emerald™ Ortho-K treatment has a unique, empirically fit lens design with no trial lenses required. With headquarters in Virginia, USA, and offices in Shanghai and Beijing, China, Euclid is leading the efforts in myopia management across the globe.
Manufactured in the U.S., the Euclid Emerald™ lens design has received FDA approval in the U.S., CE mark for Europe, as well as regulatory approvals from numerous countries around the world.